Jay Luly, Enanta Pharmaceuticals CEO

Enan­ta sells off over 50% of roy­al­ty pay­ments from Mavyret in ex­change for $200M

Enan­ta Phar­ma­ceu­ti­cals is sell­ing off roy­al­ty pay­ments from its Ab­b­Vie-part­nered drug Mavyret, its biggest rev­enue dri­ver, to a Cana­di­an pen­sion plan for $200 mil­lion.

Enan­ta has sold 54.5% of its fu­ture world­wide Mavyret roy­al­ty pay­ments from Ab­b­Vie to OMERS, a Cana­di­an de­fined ben­e­fit pen­sion plan, in ex­change for $200 mil­lion be­gin­ning in Ju­ly 2023 un­til June 2032. The roy­al­ty pay­ments are based on net sales of Mavyret dur­ing that time pe­ri­od, with to­tal pay­ments capped at 1.42 times the pur­chase price, or $284 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.